ESMO Videos on Genitourinary Cancers: Highlights from ASCO GU 2018

Bernard Escudier: Highlights on Renal Cell Cancer: IMmotion151 and other combination studies

Reporting from ASCO GU 2018, Bernard Escudier states that the results from studies presented are likely to be practice changing for the treatment of patients with renal cell cancer (RCC), regarding first-line options and patients' selection.

 

Stéphane Oudard: Highlights on non metastatic castration-resistant prostate cancer, the SPARTAN and PROSPER trials.

Reporting from ASCO GU 2018, Stephane Oudard highlights two large randomised phase III studies relevant for clinical practice (SPARTAN with apalutamide and PROSPER with enzalutamide) in term of providing new treatment options for the group of patients with non-metastatic castration-resistant prostate cancer (CRPC) who are at high risk of developing metastasis.

 

Read the medwireNews article on the SPARTAN study results

9 Feb 2018: Apalutamide Extends Metastasis-Free Survival In High-Risk Prostate Cancer